Adherence to documenting asthma severity or control and providing ample education to patients was low among physicians from 2012-2015, with primary care providers monitoring nearly two-thirds of asthma-related visits, according to a federal report.
Adherence to documenting asthma severity or control and providing ample education to patients was low among physicians from 2012-2015, with primary care providers monitoring nearly two-thirds of asthma-related visits, according to a national health statistics report published last week by the CDC.
A report on national estimates of asthma visits to physician offices was last released in 1996, utilizing data from the National Ambulatory Medical Care Survey (NAMCS) to determine physician familiarity with, and use of, the 1991 National Asthma Education and Prevention Program (NAEPP) guidelines. The report assessed asthma visits to non-federally employed U.S. physicians from 2001 to 2016, asthma visit characteristics from 2012 to 2015, and consistency of visit characteristics with NAEPP guidelines.
Asthma affects 8.3% of Americans with an attributed 1.8 million emergency room visits in 2016. Its episodic symptoms can become life-threatening, which heightens the need to monitor symptoms for preventative care. As most asthma management and patient education occurs in primary care settings, it is vital for physicians to utilize this space to ensure patients are aware of the severity of their condition.
Researchers utilized data from visits, as well as, NAMCS data from 2012-2015 and a supplement of 2012 National Asthma Survey of Physicians (NAS) data for the study.
Results showcased a stark decline in asthma visit rates from 2001 to 2016 (40.2 to 30.7 per 1000 persons) and at-risk visit rates (55.5 to 36.7 visits per 100 persons with asthma). From 2012 to 2015, there was an annual average of 10.2 million asthma visits in which 63.5% were by non-Hispanic white persons, 53.8% by female patients, and 32.5% by children under the age of 15. Population and at-risk visit rates were similar in sex, racial, and ethnic groups, with children aged 4 and younger found to have the highest at-risk asthma visit rate.
Of physicians undertaking asthma visits, 60% were handled by primary care physicians. Across the study, documentation and education of asthma were relatively low:
Researchers additionally found that bronchodilators were the most commonly mentioned medical class (24.9%), and albuterol, which is a quick-acting relief medication, was the most frequently mentioned treatment (16.9%).
Lead study author Lara Akinbami, MD, medical officer for the infant, children, and women’s health statistics branch of the office of analysis and epidemiology at the National Center for Health Statistics (NCHS), spoke in a NCHS blog about the study’s findings. “Given its high burden in morbidity, health care use, and mortality, it is important to assess the content of asthma physician office visits given that physicians are on the “front line” of asthma care and provide the majority of asthma care,” said Akinbami.
Akinbami noted that her biggest surprise in the data was that 59.1% of asthma patients had no level of control documented by physicians, especially when considering the efforts taken to have asthma controlled, assessed, and documented through NAEPP guidelines. “Additional research can explore the underlying reasons for trends, and future policy can target low implementation rates of guideline recommendations,” said Akinbami.
Reference
Akinbami LJ, Santo L, Williams S, et al. Characteristics of asthma visits to physician offices in the United States: 2012—2015 National Ambulatory Medical Care Survey. National Health Statistics Reports; no 128. Hyattsville, MD: National Center for Health Statistics. [published online September 20, 2019].
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More
2 Commerce Drive
Cranbury, NJ 08512